Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:EEA1-PAH

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: EEA1-PAH
	FusionPDB ID: 25007
	FusionGDB2.0 ID: 25007
		Hgene	Tgene
	Gene symbol	EEA1	PAH
	Gene ID	8411	5053
	Gene name	early endosome antigen 1	phenylalanine hydroxylase
	Synonyms	MST105\|MSTP105\|ZFYVE2	PH\|PKU\|PKU1
	Cytomap	12q22	12q23.2
	Type of gene	protein-coding	protein-coding
	Description	early endosome antigen 1early endosome antigen 1, 162kDearly endosome-associated proteinendosome-associated protein p162zinc finger FYVE domain-containing protein 2	phenylalanine-4-hydroxylasephe-4-monooxygenasephenylalanine 4-monooxygenase
	Modification date	20200313	20200313
	UniProtAcc	Q15075 Main function of 5'-partner protein: FUNCTION: Binds phospholipid vesicles containing phosphatidylinositol 3-phosphate and participates in endosomal trafficking.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000322349, ENST00000547833,	ENST00000551988, ENST00000307000, ENST00000553106,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	14 X 12 X 10=1680	6 X 5 X 5=150
	# samples	21	7
	** MAII score	log2(21/1680*10)=-3 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(7/150*10)=-1.09953567355091 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: EEA1 [Title/Abstract] AND PAH [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: EEA1 [Title/Abstract] AND PAH [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	EEA1(93258636)-PAH(103249110), # samples:3
Anticipated loss of major functional domain due to fusion event.	EEA1-PAH seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. EEA1-PAH seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. EEA1-PAH seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. EEA1-PAH seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:93258636/chr12:103249110)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across EEA1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across PAH (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000322349	EEA1	chr12	93258636	-	ENST00000553106	PAH	chr12	103249110	-	3650	510	265	1359	364
ENST00000322349	EEA1	chr12	93258636	-	ENST00000307000	PAH	chr12	103249110	-	2214	510	265	1359	364
ENST00000322349	EEA1	chr12	93258635	-	ENST00000553106	PAH	chr12	103249110	-	3650	510	265	1359	364
ENST00000322349	EEA1	chr12	93258635	-	ENST00000307000	PAH	chr12	103249110	-	2214	510	265	1359	364

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000322349	ENST00000553106	EEA1	chr12	93258636	-	PAH	chr12	103249110	-	0.000199635	0.9998004
ENST00000322349	ENST00000307000	EEA1	chr12	93258636	-	PAH	chr12	103249110	-	0.000414344	0.9995857
ENST00000322349	ENST00000553106	EEA1	chr12	93258635	-	PAH	chr12	103249110	-	0.000199635	0.9998004
ENST00000322349	ENST00000307000	EEA1	chr12	93258635	-	PAH	chr12	103249110	-	0.000414344	0.9995857

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for EEA1-PAH

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
EEA1	chr12	93258635	PAH	chr12	103249110	510	82	SGHGGESNLALKRGQPIPRVEYMEEE
EEA1	chr12	93258636	PAH	chr12	103249110	510	82	SGHGGESNLALKRGQPIPRVEYMEEE

Top

Potential FusionNeoAntigen Information of EEA1-PAH in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

EEA1-PAH_93258635_103249110.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:05	KRGQPIPRV	0.9994	0.5993	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:04	KRGQPIPRV	0.9992	0.6888	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:07	KRGQPIPRV	0.9992	0.7385	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B08:01	LALKRGQPI	0.9978	0.7429	8	17
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:01	RGQPIPRVEY	0.9988	0.8955	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:25	RGQPIPRVEY	0.9959	0.934	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:03	RGQPIPRVEY	0.9382	0.8296	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-A74:03	ALKRGQPIPR	0.922	0.8737	9	19
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-A74:09	ALKRGQPIPR	0.922	0.8737	9	19
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-A74:11	ALKRGQPIPR	0.922	0.8737	9	19
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:05	KRGQPIPRVEY	1	0.5763	11	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:04	KRGQPIPRVEY	1	0.6863	11	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B81:01	RGQPIPRVEYM	0.9778	0.6419	12	23
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B07:02	RGQPIPRVEYM	0.9126	0.5892	12	23
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:14	KRGQPIPRV	0.9993	0.6233	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:03	KRGQPIPRV	0.973	0.6243	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-C07:05	KRGQPIPRV	0.9525	0.9545	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-C07:95	KRGQPIPRV	0.8785	0.788	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:07	RGQPIPRVEY	0.9969	0.7205	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:04	RGQPIPRVEY	0.9733	0.9184	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:05	RGQPIPRVEY	0.9386	0.9109	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-A31:01	ALKRGQPIPR	0.9274	0.8412	9	19
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:03	KRGQPIPRVEY	0.9996	0.5981	11	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-C07:46	KRGQPIPRVEY	0.9972	0.8438	11	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:07	KRGQPIPRVEY	0.9954	0.6708	11	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B07:04	RGQPIPRVEYM	0.9912	0.5993	12	23
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B42:02	RGQPIPRVEYM	0.9574	0.7491	12	23
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B42:01	RGQPIPRVEYM	0.9343	0.7389	12	23
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:10	KRGQPIPRV	0.9992	0.7515	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:09	KRGQPIPRV	0.9991	0.5958	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:06	KRGQPIPRV	0.9991	0.7562	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B08:18	LALKRGQPI	0.9978	0.7429	8	17
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-C03:17	LALKRGQPI	0.9665	0.9484	8	17
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-C07:01	KRGQPIPRV	0.9333	0.7707	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-C06:08	KRGQPIPRV	0.7517	0.9946	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-C07:22	KRGQPIPRV	0.4809	0.8007	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-C06:06	KRGQPIPRV	0.3685	0.9927	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-C06:17	KRGQPIPRV	0.0363	0.9949	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-C06:02	KRGQPIPRV	0.0363	0.9949	11	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:34	RGQPIPRVEY	0.9988	0.8955	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:33	RGQPIPRVEY	0.9988	0.8955	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:27	RGQPIPRVEY	0.9988	0.9166	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:125	RGQPIPRVEY	0.9988	0.8955	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:53	RGQPIPRVEY	0.9986	0.8851	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:135	RGQPIPRVEY	0.9986	0.9067	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:12	RGQPIPRVEY	0.9978	0.8429	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:50	RGQPIPRVEY	0.9976	0.8737	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:39	RGQPIPRVEY	0.9967	0.8823	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:35	RGQPIPRVEY	0.9966	0.9085	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:54	RGQPIPRVEY	0.9859	0.8553	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:68	RGQPIPRVEY	0.9455	0.6342	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:20	RGQPIPRVEY	0.9376	0.9414	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-A74:01	ALKRGQPIPR	0.922	0.8737	9	19
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B35:28	RGQPIPRVEY	0.9135	0.9435	12	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B27:10	KRGQPIPRVEY	1	0.7627	11	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:27	KRGQPIPRVEY	0.9986	0.8621	11	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:50	KRGQPIPRVEY	0.9981	0.8159	11	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:35	KRGQPIPRVEY	0.9956	0.86	11	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B07:26	RGQPIPRVEYM	0.995	0.606	12	23
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B15:68	KRGQPIPRVEY	0.9865	0.5688	11	22
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B07:09	RGQPIPRVEYM	0.9329	0.5965	12	23
EEA1-PAH	chr12	93258635	chr12	103249110	510	HLA-B07:22	RGQPIPRVEYM	0.9126	0.5892	12	23

Top

Potential FusionNeoAntigen Information of EEA1-PAH in HLA II

EEA1-PAH_93258635_103249110.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
EEA1-PAH	chr12	93258635	chr12	103249110	510	DRB1-0103	ESNLALKRGQPIPRV	5	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	DRB1-0103	GESNLALKRGQPIPR	4	19
EEA1-PAH	chr12	93258635	chr12	103249110	510	DRB1-1331	ESNLALKRGQPIPRV	5	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	DRB1-1331	GESNLALKRGQPIPR	4	19
EEA1-PAH	chr12	93258635	chr12	103249110	510	DRB1-1354	ESNLALKRGQPIPRV	5	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	DRB1-1354	GESNLALKRGQPIPR	4	19
EEA1-PAH	chr12	93258635	chr12	103249110	510	DRB1-1510	ESNLALKRGQPIPRV	5	20
EEA1-PAH	chr12	93258635	chr12	103249110	510	DRB1-1510	GESNLALKRGQPIPR	4	19

Top

Fusion breakpoint peptide structures of EEA1-PAH

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
8857	SNLALKRGQPIPRV	EEA1	PAH	chr12	93258635	chr12	103249110	510

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of EEA1-PAH

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	8857	SNLALKRGQPIPRV	-7.9962	-8.1096
HLA-B14:02	3BVN	8857	SNLALKRGQPIPRV	-5.70842	-6.74372
HLA-B52:01	3W39	8857	SNLALKRGQPIPRV	-6.83737	-6.95077
HLA-B52:01	3W39	8857	SNLALKRGQPIPRV	-4.4836	-5.5189
HLA-A11:01	4UQ2	8857	SNLALKRGQPIPRV	-10.0067	-10.1201
HLA-A11:01	4UQ2	8857	SNLALKRGQPIPRV	-9.03915	-10.0745
HLA-A24:02	5HGA	8857	SNLALKRGQPIPRV	-6.56204	-6.67544
HLA-A24:02	5HGA	8857	SNLALKRGQPIPRV	-5.42271	-6.45801
HLA-B44:05	3DX8	8857	SNLALKRGQPIPRV	-7.85648	-8.89178
HLA-B44:05	3DX8	8857	SNLALKRGQPIPRV	-5.3978	-5.5112
HLA-A02:01	6TDR	8857	SNLALKRGQPIPRV	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of EEA1-PAH

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
EEA1-PAH	chr12	93258635	chr12	103249110	11	20	KRGQPIPRV	GAAGCGTGGGCAGCCCATCCCTCGAGT
EEA1-PAH	chr12	93258635	chr12	103249110	11	22	KRGQPIPRVEY	GAAGCGTGGGCAGCCCATCCCTCGAGTGGAATA
EEA1-PAH	chr12	93258635	chr12	103249110	12	22	RGQPIPRVEY	GCGTGGGCAGCCCATCCCTCGAGTGGAATA
EEA1-PAH	chr12	93258635	chr12	103249110	12	23	RGQPIPRVEYM	GCGTGGGCAGCCCATCCCTCGAGTGGAATACAT
EEA1-PAH	chr12	93258635	chr12	103249110	8	17	LALKRGQPI	TCTTGCTTTGAAGCGTGGGCAGCCCAT
EEA1-PAH	chr12	93258635	chr12	103249110	9	19	ALKRGQPIPR	TGCTTTGAAGCGTGGGCAGCCCATCCCTCG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
EEA1-PAH	chr12	93258635	chr12	103249110	4	19	GESNLALKRGQPIPR	AGGAGAGTCTAATCTTGCTTTGAAGCGTGGGCAGCCCATCCCTCG
EEA1-PAH	chr12	93258635	chr12	103249110	5	20	ESNLALKRGQPIPRV	AGAGTCTAATCTTGCTTTGAAGCGTGGGCAGCCCATCCCTCGAGT

Top

Information of the samples that have these potential fusion neoantigens of EEA1-PAH

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BRCA	EEA1-PAH	chr12	93258635	ENST00000322349	chr12	103249110	ENST00000307000	TCGA-BH-A0B7

Top

Potential target of CAR-T therapy development for EEA1-PAH

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to EEA1-PAH

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to EEA1-PAH

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)